Recent Company News

• 02:51 AM ET Apr 24, 2025
  

  Shionogi & Co. guides year-end dividend ¥33/share vs prior guidance ¥29/share (¥2385.0000, 0)

• 11:05 PM ET Apr 13, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 10:02 PM ET Apr 08, 2025
  

  Follow-up: US President Donald Trump says the US will unveil "major" tariff on imports of pharmaceutical goods - NBC News

• 11:54 PM ET Apr 01, 2025
  

  Shionogi & Co. inks license agreement with Link Medical Products for cefiderocol in Australia, New Zealand (¥2253.5000, -33)

• 07:36 PM ET Mar 31, 2025
  

  Shionogi & Co. initiates NDA submission for ensitrelvir for post-exposure prophylaxis (¥2246.0000, 0)

• 04:17 PM ET Mar 18, 2025
  

  HHS reportedly considering "major" reductions in domestic HIV prevention funding -- wires

• 03:14 PM ET Mar 12, 2025
  

  Viiv Healthcare announces new data from two implementation studies showing zero cases of HIV acquisition for Apretude

• 11:53 AM ET Mar 12, 2025
  

  Shionogi's ensitrelvir becomes first and only oral COVID-19 antiviral proven to prevent infection after exposure (¥2251.0000, 0)

• 11:35 AM ET Mar 12, 2025
  

  ViiV Healthcare announces findings from EMBRACE phase IIb study of N6LS

• 01:41 AM ET Feb 18, 2025
  

  Japan approves marketing of Shionogi & Co.'s digital therapeutic app ENDEAVORRIDE for ADHD (¥2204.0000, 0)